Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 194,300 shares, a decrease of 17.8% from the November 30th total of 236,400 shares. Based on an average daily trading volume, of 39,000 shares, the short-interest ratio is presently 5.0 days. Approximately 5.4% of the shares of the company are short sold.

Insider Activity at Greenwich LifeSciences

In other news, CEO Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock in a transaction on Friday, December 9th. The stock was purchased at an average cost of $13.11 per share, with a total value of $26,220.00. Following the purchase, the chief executive officer now directly owns 2,724,886 shares of the company's stock, valued at approximately $35,723,255.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired a total of 13,500 shares of company stock valued at $145,510 in the last quarter. Insiders own 52.14% of the company's stock.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors have recently made changes to their positions in GLSI. Vanguard Group Inc. lifted its stake in shares of Greenwich LifeSciences by 150.2% in the 1st quarter. Vanguard Group Inc. now owns 375,200 shares of the company's stock worth $7,362,000 after acquiring an additional 225,213 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $891,000. Millennium Management LLC acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $765,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $199,000. Finally, Pura Vida Investments LLC acquired a new stake in shares of Greenwich LifeSciences in the 3rd quarter worth approximately $179,000. 6.18% of the stock is owned by institutional investors and hedge funds.

Greenwich LifeSciences Trading Down 4.0 %

Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. Sell-side analysts expect that Greenwich LifeSciences will post -0.57 earnings per share for the current year.

Greenwich LifeSciences Company Profile

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Further Reading

• Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
• Can Investors Cash In On PayPal?
• These 3 Tech Stocks Are in for a Happier New Year
• Tyson Foods: Growth and Momentum at a Reasonable Price
• Can Duke Energy Stock Continue Powering Higher?
• Ready for a Recession? Here's One Defensive Stock You Can't Miss

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.